Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 281

1.

PON1 increases cellular DNA damage by lactone substrates.

Shangula S, Noori M, Ahmad I, Margison GP, Liu Y, Siahmansur T, Soran H, Povey AC.

Arch Toxicol. 2019 Jul;93(7):2035-2043. doi: 10.1007/s00204-019-02475-w. Epub 2019 Jun 17.

PMID:
31209508
2.

O6-methylguanine-induced transcriptional mutagenesis reduces p53 tumor-suppressor function.

Ezerskyte M, Paredes JA, Malvezzi S, Burns JA, Margison GP, Olsson M, Scicchitano DA, Dreij K.

Proc Natl Acad Sci U S A. 2018 May 1;115(18):4731-4736. doi: 10.1073/pnas.1721764115. Epub 2018 Apr 17.

3.

L-β-N-methylamino-l-alanine (BMAA) nitrosation generates a cytotoxic DNA damaging alkylating agent: An unexplored mechanism for neurodegenerative disease.

Potjewyd G, Day PJ, Shangula S, Margison GP, Povey AC.

Neurotoxicology. 2017 Mar;59:105-109. doi: 10.1016/j.neuro.2017.01.007. Epub 2017 Feb 3.

PMID:
28163087
4.

IGF-1R inhibition induces schedule-dependent sensitization of human melanoma to temozolomide.

Ramcharan R, Aleksic T, Kamdoum WP, Gao S, Pfister SX, Tanner J, Bridges E, Asher R, Watson AJ, Margison GP, Woodcock M, Repapi E, Li JL, Middleton MR, Macaulay VM.

Oncotarget. 2015 Nov 24;6(37):39877-90. doi: 10.18632/oncotarget.5631.

5.

MGMT Expression Predicts PARP-Mediated Resistance to Temozolomide.

Erice O, Smith MP, White R, Goicoechea I, Barriuso J, Jones C, Margison GP, Acosta JC, Wellbrock C, Arozarena I.

Mol Cancer Ther. 2015 May;14(5):1236-46. doi: 10.1158/1535-7163.MCT-14-0810. Epub 2015 Mar 16.

6.

The bacterial alkyltransferase-like (eATL) protein protects mammalian cells against methylating agent-induced toxicity.

Tomaszowski KH, Aasland D, Margison GP, Williams E, Pinder SI, Modesti M, Fuchs RP, Kaina B.

DNA Repair (Amst). 2015 Apr;28:14-20. doi: 10.1016/j.dnarep.2015.01.009. Epub 2015 Jan 31.

PMID:
25703834
7.

Increased N7-methyldeoxyguanosine DNA adducts after occupational exposure to pesticides and influence of genetic polymorphisms of paraoxonase-1 and glutathione S-transferase M1 and T1.

Gómez-Martín A, Altakroni B, Lozano-Paniagua D, Margison GP, de Vocht F, Povey AC, Hernández AF.

Environ Mol Mutagen. 2015 Jun;56(5):437-45. doi: 10.1002/em.21929. Epub 2014 Nov 26.

PMID:
25427726
8.

Differential chemosensitivity to antifolate drugs between RAS and BRAF melanoma cells.

Arozarena I, Goicoechea I, Erice O, Ferguson J, Margison GP, Wellbrock C.

Mol Cancer. 2014 Jun 19;13:154. doi: 10.1186/1476-4598-13-154.

9.

O⁶-carboxymethylguanine in DNA forms a sequence context-dependent wobble base-pair structure with thymine.

Zhang F, Tsunoda M, Kikuchi Y, Wilkinson O, Millington CL, Margison GP, Williams DM, Takénaka A.

Acta Crystallogr D Biol Crystallogr. 2014 Jun;70(Pt 6):1669-79. doi: 10.1107/S1399004714006178. Epub 2014 May 30.

PMID:
24914978
10.

Repair and removal of azoxymethane-induced O6-methylguanine in rat colon by O6-methylguanine DNA methyltransferase and apoptosis.

Nyskohus LS, Watson AJ, Margison GP, Le Leu RK, Kim SW, Lockett TJ, Head RJ, Young GP, Hu Y.

Mutat Res. 2013 Dec 12;758(1-2):80-6. doi: 10.1016/j.mrgentox.2013.10.001. Epub 2013 Oct 16.

PMID:
24140386
11.

Bayesian inference supports a location and neighbour-dependent model of DNA methylation propagation at the MGMT gene promoter in lung tumours.

Bonello N, Sampson J, Burn J, Wilson IJ, McGrown G, Margison GP, Thorncroft M, Crossbie P, Povey AC, Santibanez-Koref M, Walters K.

J Theor Biol. 2013 Nov 7;336:87-95. doi: 10.1016/j.jtbi.2013.07.019. Epub 2013 Jul 30.

PMID:
23911575
12.

Topographical study of O(6)-alkylguanine DNA alkyltransferase repair activity and N7-methylguanine levels in resected lung tissue.

Crosbie PA, Harrison K, Shah R, Watson AJ, Agius R, Barber PV, Margison GP, Povey AC.

Chem Biol Interact. 2013 Jul 5;204(2):98-104. doi: 10.1016/j.cbi.2013.04.013. Epub 2013 May 9.

PMID:
23665414
13.

Structures of DNA duplexes containing O6-carboxymethylguanine, a lesion associated with gastrointestinal cancer, reveal a mechanism for inducing pyrimidine transition mutations.

Zhang F, Tsunoda M, Suzuki K, Kikuchi Y, Wilkinson O, Millington CL, Margison GP, Williams DM, Czarina Morishita E, Takénaka A.

Nucleic Acids Res. 2013 May 1;41(10):5524-32. doi: 10.1093/nar/gkt198. Epub 2013 Apr 10.

14.

Triazene compounds in the treatment of acute myeloid leukemia: a short review and a case report.

Bonmassar L, Marchesi F, Pascale E, Franzese O, Margison GP, Bianchi A, D'Atri S, Bernardini S, Lattuada D, Bonmassar E, Aquino A.

Curr Med Chem. 2013;20(19):2389-401. Review.

PMID:
23521681
15.

The nitrosated bile acid DNA lesion O6-carboxymethylguanine is a substrate for the human DNA repair protein O6-methylguanine-DNA methyltransferase.

Senthong P, Millington CL, Wilkinson OJ, Marriott AS, Watson AJ, Reamtong O, Eyers CE, Williams DM, Margison GP, Povey AC.

Nucleic Acids Res. 2013 Mar 1;41(5):3047-55. doi: 10.1093/nar/gks1476. Epub 2013 Jan 17.

16.

Alkyltransferase-like protein (Atl1) distinguishes alkylated guanines for DNA repair using cation-π interactions.

Wilkinson OJ, Latypov V, Tubbs JL, Millington CL, Morita R, Blackburn H, Marriott A, McGown G, Thorncroft M, Watson AJ, Connolly BA, Grasby JA, Masui R, Hunter CA, Tainer JA, Margison GP, Williams DM.

Proc Natl Acad Sci U S A. 2012 Nov 13;109(46):18755-60. doi: 10.1073/pnas.1209451109. Epub 2012 Oct 29.

17.

Synthesis of oligodeoxyribonucleotides containing a conformationally-locked anti analogue of O6-methyl-2'-deoxyguanosine and their recognition by MGMT and Atl1.

Abdu K, Aiertza MK, Wilkinson OJ, Grasby JA, Senthong P, Povey AC, Margison GP, Williams DM.

Chem Commun (Camb). 2012 Nov 25;48(91):11214-6. doi: 10.1039/c2cc36252j. Epub 2012 Oct 11.

PMID:
23059787
18.

Molecular characterization of an adaptive response to alkylating agents in the opportunistic pathogen Aspergillus fumigatus.

O'Hanlon KA, Margison GP, Hatch A, Fitzpatrick DA, Owens RA, Doyle S, Jones GW.

Nucleic Acids Res. 2012 Sep;40(16):7806-20. doi: 10.1093/nar/gks522. Epub 2012 Jun 4.

19.

Atl1 regulates choice between global genome and transcription-coupled repair of O(6)-alkylguanines.

Latypov VF, Tubbs JL, Watson AJ, Marriott AS, McGown G, Thorncroft M, Wilkinson OJ, Senthong P, Butt A, Arvai AS, Millington CL, Povey AC, Williams DM, Santibanez-Koref MF, Tainer JA, Margison GP.

Mol Cell. 2012 Jul 13;47(1):50-60. doi: 10.1016/j.molcel.2012.04.028. Epub 2012 May 31.

20.

Convenient and efficient syntheses of oligodeoxyribonucleotides containing O(6)-(carboxymethyl)guanine and O(6)-(4-oxo-4-(3-pyridyl)butyl)guanine.

Millington CL, Watson AJ, Marriott AS, Margison GP, Povey AC, Williams DM.

Nucleosides Nucleotides Nucleic Acids. 2012 Apr;31(4):328-38. doi: 10.1080/15257770.2012.656784.

PMID:
22444194
21.

Elevated N3-methylpurine-DNA glycosylase DNA repair activity is associated with lung cancer.

Crosbie PA, Watson AJ, Agius R, Barber PV, Margison GP, Povey AC.

Mutat Res. 2012 Apr 1;732(1-2):43-6. doi: 10.1016/j.mrfmmm.2012.01.001. Epub 2012 Jan 14.

PMID:
22266085
22.

Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients.

Agnihotri S, Gajadhar AS, Ternamian C, Gorlia T, Diefes KL, Mischel PS, Kelly J, McGown G, Thorncroft M, Carlson BL, Sarkaria JN, Margison GP, Aldape K, Hawkins C, Hegi M, Guha A.

J Clin Invest. 2012 Jan;122(1):253-66. doi: 10.1172/JCI59334. Epub 2011 Dec 12. Erratum in: J Clin Invest. 2012 Feb 1;122(2):782.

23.

Characterization of a new trabectedin-resistant myxoid liposarcoma cell line that shows collateral sensitivity to methylating agents.

Uboldi S, Bernasconi S, Romano M, Marchini S, Fuso Nerini I, Damia G, Ganzinelli M, Marangon E, Sala F, Clivio L, Chiorino G, Di Giandomenico S, Rocchi M, Capozzi O, Margison GP, Watson AJ, Caccuri AM, Pastore A, Fossati A, Mantovani R, Grosso F, Tercero JC, Erba E, D'Incalci M.

Int J Cancer. 2012 Jul 1;131(1):59-69. doi: 10.1002/ijc.26340. Epub 2011 Aug 30.

24.

Obesity and hepatosteatosis in mice with enhanced oxidative DNA damage processing in mitochondria.

Zhang H, Xie C, Spencer HJ, Zuo C, Higuchi M, Ranganathan G, Kern PA, Chou MW, Huang Q, Szczesny B, Mitra S, Watson AJ, Margison GP, Fan CY.

Am J Pathol. 2011 Apr;178(4):1715-27. doi: 10.1016/j.ajpath.2010.12.038.

25.

A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours.

Khan OA, Gore M, Lorigan P, Stone J, Greystoke A, Burke W, Carmichael J, Watson AJ, McGown G, Thorncroft M, Margison GP, Califano R, Larkin J, Wellman S, Middleton MR.

Br J Cancer. 2011 Mar 1;104(5):750-5. doi: 10.1038/bjc.2011.8. Epub 2011 Feb 15.

26.

Towards more specific O6-methylguanine-DNA methyltransferase (MGMT) inactivators.

Lopez S, Margison GP, McElhinney RS, Cordeiro A, McMurry TB, Rozas I.

Bioorg Med Chem. 2011 Mar 1;19(5):1658-65. doi: 10.1016/j.bmc.2011.01.038. Epub 2011 Jan 27.

PMID:
21320783
27.

Expression of O-Alkylguanine-DNA Alkyltransferase in Normal and Malignant Bladder Tissue of Egyptian Patients.

Saad AA, Kassem HSh, Povey AC, Margison GP.

J Nucleic Acids. 2010 Oct 17;2010:840230. doi: 10.4061/2010/840230.

28.

Targeting O⁶-methylguanine-DNA methyltransferase with specific inhibitors as a strategy in cancer therapy.

Kaina B, Margison GP, Christmann M.

Cell Mol Life Sci. 2010 Nov;67(21):3663-81. doi: 10.1007/s00018-010-0491-7. Epub 2010 Aug 18. Review.

PMID:
20717836
29.

Tumor O(6)-methylguanine-DNA methyltransferase inactivation by oral lomeguatrib.

Watson AJ, Sabharwal A, Thorncroft M, McGown G, Kerr R, Bojanic S, Soonawalla Z, King A, Miller A, Waller S, Leung H, Margison GP, Middleton MR.

Clin Cancer Res. 2010 Jan 15;16(2):743-9. doi: 10.1158/1078-0432.CCR-09-1389. Epub 2010 Jan 12.

30.

Folate deficiency alters hepatic and colon MGMT and OGG-1 DNA repair protein expression in rats but has no effect on genome-wide DNA methylation.

Duthie SJ, Grant G, Pirie LP, Watson AJ, Margison GP.

Cancer Prev Res (Phila). 2010 Jan;3(1):92-100. doi: 10.1158/1940-6207.CAPR-09-0231.

31.

A phase I trial of lomeguatrib and irinotecan in metastatic colorectal cancer.

Sabharwal A, Corrie PG, Midgley RS, Palmer C, Brady J, Mortimer P, Watson AJ, Margison GP, Middleton MR.

Cancer Chemother Pharmacol. 2010 Oct;66(5):829-35. doi: 10.1007/s00280-009-1225-0. Epub 2009 Dec 29.

PMID:
20039040
32.

Predicting the myelotoxicity of chemotherapy: the use of pretreatment O6-methylguanine-DNA methyltransferase determination in peripheral blood mononuclear cells.

Sabharwal A, Waters R, Danson S, Clamp A, Lorigan P, Thatcher N, Margison GP, Middleton MR.

Melanoma Res. 2011 Dec;21(6):502-8. doi: 10.1097/CMR.0b013e32832ccd58.

PMID:
19561552
33.

Flipping of alkylated DNA damage bridges base and nucleotide excision repair.

Tubbs JL, Latypov V, Kanugula S, Butt A, Melikishvili M, Kraehenbuehl R, Fleck O, Marriott A, Watson AJ, Verbeek B, McGown G, Thorncroft M, Santibanez-Koref MF, Millington C, Arvai AS, Kroeger MD, Peterson LA, Williams DM, Fried MG, Margison GP, Pegg AE, Tainer JA.

Nature. 2009 Jun 11;459(7248):808-13. doi: 10.1038/nature08076.

34.

GSTM1 copy number and lung cancer risk.

Crosbie PA, Barber PV, Harrison KL, Gibbs AR, Agius RM, Margison GP, Povey AC.

Mutat Res. 2009 May 12;664(1-2):1-5. doi: 10.1016/j.mrfmmm.2009.01.006. Epub 2009 Feb 4.

PMID:
19428374
35.

O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib.

Watson AJ, Middleton MR, McGown G, Thorncroft M, Ranson M, Hersey P, McArthur G, Davis ID, Thomson D, Beith J, Haydon A, Kefford R, Lorigan P, Mortimer P, Sabharwal A, Hayward O, Margison GP.

Br J Cancer. 2009 Apr 21;100(8):1250-6. doi: 10.1038/sj.bjc.6605015.

36.

A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma.

Kefford RF, Thomas NP, Corrie PG, Palmer C, Abdi E, Kotasek D, Beith J, Ranson M, Mortimer P, Watson AJ, Margison GP, Middleton MR.

Br J Cancer. 2009 Apr 21;100(8):1245-9. doi: 10.1038/sj.bjc.6605016. Epub 2009 Mar 31.

37.

Dietary variables associated with DNA N7-methylguanine levels and O6-alkylguanine DNA-alkyltransferase activity in human colorectal mucosa.

Billson HA, Harrison KL, Lees NP, Hall CN, Margison GP, Povey AC.

Carcinogenesis. 2009 Apr;30(4):615-20. doi: 10.1093/carcin/bgp020. Epub 2009 Jan 23.

PMID:
19168588
38.

Reciprocal relationship between O6-methylguanine-DNA methyltransferase P140K expression level and chemoprotection of hematopoietic stem cells.

Milsom MD, Jerabek-Willemsen M, Harris CE, Schambach A, Broun E, Bailey J, Jansen M, Schleimer D, Nattamai K, Wilhelm J, Watson A, Geiger H, Margison GP, Moritz T, Baum C, Thomale J, Williams DA.

Cancer Res. 2008 Aug 1;68(15):6171-80. doi: 10.1158/0008-5472.CAN-08-0320.

39.

A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer.

Khan OA, Ranson M, Michael M, Olver I, Levitt NC, Mortimer P, Watson AJ, Margison GP, Midgley R, Middleton MR.

Br J Cancer. 2008 May 20;98(10):1614-8. doi: 10.1038/sj.bjc.6604366. Epub 2008 May 13. Erratum in: Br J Cancer. 2009 Aug 4;101(3):550.

40.

O6-Methylguanine-DNA methyltransferase inactivation and chemotherapy.

Verbeek B, Southgate TD, Gilham DE, Margison GP.

Br Med Bull. 2008;85:17-33. doi: 10.1093/bmb/ldm036. Epub 2008 Feb 1. Review.

PMID:
18245773
41.

The synthesis and properties of tricyclic analogues of S6-methylthioguanine and O6-methylguanine.

Hornillo-Araujo AR, Burrell AJ, Aiertza MK, Shibata T, Hammond DM, Edmont D, Adams H, Margison GP, Williams DM.

Nucleosides Nucleotides Nucleic Acids. 2007;26(8-9):1099-102.

PMID:
18058544
42.

Association between lung cancer risk and single nucleotide polymorphisms in the first intron and codon 178 of the DNA repair gene, O6-alkylguanine-DNA alkyltransferase.

Crosbie PA, McGown G, Thorncroft MR, O'Donnell PN, Barber PV, Lewis SJ, Harrison KL, Agius RM, Santibáñez-Koref MF, Margison GP, Povey AC.

Int J Cancer. 2008 Feb 15;122(4):791-5.

43.

Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma.

Ranson M, Hersey P, Thompson D, Beith J, McArthur GA, Haydon A, Davis ID, Kefford RF, Mortimer P, Harris PA, Baka S, Seebaran A, Sabharwal A, Watson AJ, Margison GP, Middleton MR.

J Clin Oncol. 2007 Jun 20;25(18):2540-5.

PMID:
17577032
44.

Lung cancer risk and variation in MGMT activity and sequence.

Povey AC, Margison GP, Santibáñez-Koref MF.

DNA Repair (Amst). 2007 Aug 1;6(8):1134-44. Epub 2007 Jun 13. Review.

PMID:
17569600
45.

Alkyltransferase-like proteins.

Margison GP, Butt A, Pearson SJ, Wharton S, Watson AJ, Marriott A, Caetano CM, Hollins JJ, Rukazenkova N, Begum G, Santibáñez-Koref MF.

DNA Repair (Amst). 2007 Aug 1;6(8):1222-8. Epub 2007 May 17. Review.

PMID:
17500045
46.

Targeting human 8-oxoguanine DNA glycosylase (hOGG1) to mitochondria enhances cisplatin cytotoxicity in hepatoma cells.

Zhang H, Mizumachi T, Carcel-Trullols J, Li L, Naito A, Spencer HJ, Spring PM, Smoller BR, Watson AJ, Margison GP, Higuchi M, Fan CY.

Carcinogenesis. 2007 Aug;28(8):1629-37. Epub 2007 Mar 26.

PMID:
17389610
47.

Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer.

White SC, Lorigan P, Margison GP, Margison JM, Martin F, Thatcher N, Anderson H, Ranson M.

Br J Cancer. 2006 Oct 9;95(7):822-8. Epub 2006 Sep 12.

48.
49.

No association between N7-methyldeoxyguanosine and 8-oxodeoxyguanosine levels in human lymphocyte DNA.

Harrison KL, Crosbie PA, Agius RM, Barber PV, Carus M, Margison GP, Povey AC.

Mutat Res. 2006 Aug 30;600(1-2):125-30. Epub 2006 Jun 12.

PMID:
16765387
50.

Supplemental Content

Loading ...
Support Center